Clinical Trials Directory

Trials / Unknown

UnknownNCT05185791

ERAS® Guidelines Validation of CRS With or Without HIPEC

Feasibility and Clinical Results of Implementation of ERAS® Guidelines for Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: an International Prospective Cohort Study

Status
Unknown
Phase
Study type
Observational
Enrollment
288 (estimated)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Enhanced recovery after surgery (ERAS®) pathways have been shown to considerably reduce complications, length of stay and costs after most of surgical procedures by standardised application of best evidence-based perioperative care. Recently an international panel of expert have succeeded to elaborate dedicated recommendations for cytoreductive surgery (CRS) ± hyperthermic intraperitoneal chemotherapy (HIPEC) in a two-part series of guidelines based on expert consensus (Hübner et al., EJSO, 2020). The aim of this prospective validation study was therefore to study acceptance, feasibility and clinical results of these guidelines in clinical practice. Hypothesis of the study: Introduction of ERAS® guidelines is feasible and safe. Increasing compliance with ERAS® guidelines (after implementation) will improve recovery and early clinical outcomes of patients undergoing CRS/HIPEC.

Detailed description

The study includes two succesive phases interrupted by a stage to implement ERAS® guidelines.

Conditions

Interventions

TypeNameDescription
OTHERPre-ERAS® phase (current clinical practice)Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
OTHERPost-ERAS® implementation phaseDescriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.

Timeline

Start date
2021-10-01
Primary completion
2022-06-30
Completion
2022-08-31
First posted
2022-01-11
Last updated
2022-01-11

Locations

3 sites across 3 countries: United States, Canada, Switzerland

Source: ClinicalTrials.gov record NCT05185791. Inclusion in this directory is not an endorsement.